Cencora, Inc. (NYSE:COR) Position Increased by Fox Run Management L.L.C.

Fox Run Management L.L.C. increased its position in shares of Cencora, Inc. (NYSE:COR) by 19.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,665 shares of the company’s stock after acquiring an additional 591 shares during the period. Fox Run Management L.L.C.’s holdings in Cencora were worth $823,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Cencora during the fourth quarter worth $19,543,000. Sei Investments Co. raised its holdings in shares of Cencora by 5.2% during the fourth quarter. Sei Investments Co. now owns 321,877 shares of the company’s stock worth $72,319,000 after acquiring an additional 16,039 shares in the last quarter. American Century Companies Inc. raised its holdings in shares of Cencora by 43.8% during the fourth quarter. American Century Companies Inc. now owns 862,637 shares of the company’s stock worth $193,818,000 after acquiring an additional 262,823 shares in the last quarter. Mizuho Securities USA LLC increased its position in Cencora by 46.9% during the fourth quarter. Mizuho Securities USA LLC now owns 16,621 shares of the company’s stock worth $3,734,000 after buying an additional 5,309 shares during the last quarter. Finally, Sciencast Management LP acquired a new position in Cencora during the fourth quarter worth $243,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities analysts have commented on COR shares. Mizuho started coverage on shares of Cencora in a research report on Wednesday, December 4th. They set an “outperform” rating and a $280.00 target price on the stock. Wells Fargo & Company increased their target price on shares of Cencora from $251.00 to $274.00 and gave the stock an “equal weight” rating in a research report on Friday, March 14th. Evercore ISI increased their target price on shares of Cencora from $270.00 to $280.00 and gave the stock an “outperform” rating in a research report on Thursday, February 6th. JPMorgan Chase & Co. increased their target price on shares of Cencora from $289.00 to $301.00 and gave the stock an “overweight” rating in a research report on Friday, January 24th. Finally, StockNews.com raised shares of Cencora from a “hold” rating to a “buy” rating in a research report on Wednesday, March 12th. Two research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $280.20.

Cencora Stock Down 0.3 %

COR stock opened at $266.91 on Monday. Cencora, Inc. has a twelve month low of $214.77 and a twelve month high of $271.08. The company has a market cap of $51.76 billion, a PE ratio of 37.97, a price-to-earnings-growth ratio of 1.31 and a beta of 0.51. The business’s 50-day simple moving average is $250.62 and its 200 day simple moving average is $240.01. The company has a quick ratio of 0.54, a current ratio of 0.92 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR) last released its earnings results on Wednesday, February 5th. The company reported $3.73 earnings per share for the quarter, topping analysts’ consensus estimates of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, March 3rd. Investors of record on Friday, February 14th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 0.82%. The ex-dividend date was Friday, February 14th. Cencora’s dividend payout ratio (DPR) is presently 31.29%.

Insider Buying and Selling

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $260.06, for a total transaction of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares in the company, valued at $5,241,249.24. This trade represents a 9.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Silvana Battaglia sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $242.24, for a total transaction of $1,211,200.00. Following the transaction, the executive vice president now owns 15,374 shares of the company’s stock, valued at approximately $3,724,197.76. This represents a 24.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 11,970 shares of company stock valued at $2,998,670 over the last three months. 10.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.